ReviewRegenerative medicine2019
Nomenclature and heterogeneity: consequences for the use of mesenchymal stem cells in regenerative medicine.
Review in Regenerative medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- Mechanomedicine-guided mechanical preconditioning of dental-derived stromal cells for tissue regeneration.Stem cell research & therapy · 2026Review
- The Size of Human Mesenchymal Tissue Stem Cell Turnover Units is a Major Determinant for Maintaining High Stem Cell Fractions With Serial Culture Expansion.Stem cells international · 2026Article
- RNA sequencing identifiesCytotechnology · 2025Article
- Skeletal stem and progenitor cells in bone physiology, ageing and disease.Nature reviews. Endocrinology · 2025Review
- Human pancreatic islet-derived stromal cells reveal combined features of mesenchymal stromal cells and pancreatic stellate cells.Stem cell research & therapy · 2024Article
- Leveraging Cell Migration Dynamics to Discriminate Between Senescent and Presenescent Human Mesenchymal Stem Cells.Cellular and molecular bioengineering · 2024Article
- The Myofibroblast Fate of Therapeutic Mesenchymal Stromal Cells: Regeneration, Repair, or Despair?International journal of molecular sciences · 2024Review
- Functionalized Annealed Microgels for Spatial Control of Osteogenic and Chondrogenic Differentiation.Advanced functional materials · 2024Article
- Mesenchymal stem cells and their derived exosomes in multiple sclerosis disease: from paper to practice.Molecular and cellular biochemistry · 2024Review
- Extracellular matrices of stromal cell subtypes regulate phenotype and contribute to the stromal microenvironment in vivo.Stem cell research & therapy · 2024Article
- Article
- Intra-articular injection of bone marrow aspirate concentrate (mesenchymal stem cells) in KL grade III and IV knee osteoarthritis: 4 year results of 37 knees.Scientific reports · 2024Article
- The Therapeutic Effects of Mesenchymal Stem Cells and their Secretome on Oral Squamous Cell Carcinoma.Current molecular medicine · 2024Review
- Evaluation of the Precision of Kinetic Stem Cell (KSC) Counting for Specific Quantification of Human Mesenchymal Stem Cells in Heterogeneous Tissue Cell Preparations.Life (Basel, Switzerland) · 2023Article
- Article
- Secretome as a Tool to Treat Neurological Conditions: Are We Ready?International journal of molecular sciences · 2023Review
- Attitudes Towards Standardization of Mesenchymal Stromal Cells-A Qualitative Exploration of Expert Views.Stem cells translational medicine · 2023Article
- Single-Cell RNA-Seq Reveals LRRC75A-Expressing Cell Population Involved in VEGF Secretion of Multipotent Mesenchymal Stromal/Stem Cells Under Ischemia.Stem cells translational medicine · 2023Article
- Managing the Heterogeneity of Mesenchymal Stem Cells for Cartilage Regenerative Therapy: A Review.Bioengineering (Basel, Switzerland) · 2023Review
- Needle to needle robot-assisted manufacture of cell therapy products.Bioengineering & translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) are in development for many clinical indications, based both on 'stem' properties (tissue repair or regeneration) and on signaling repertoire (immunomodulatory and anti-inflammatory effects). Potential conflation of MSC properties with those of tissue-derived stromal cells presents difficulties in comparing study outcomes and represents a source of confusion in cell therapy development. Cultured MSCs demonstrate significant heterogeneity in clonogenicity and multi-lineage differentiation potential. However
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.